Wedbush Upgrades Zentalis to Outperform on Promising Ovarian Cancer Survival Data
Analysts upgraded Zentalis after DENALI Part 1b data showed median survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer.
/ 3 items
#ZNTL↓
Mixed Analyst Calls Hit Biotech: Downgrades for Bristol Myers and uniQure, Upgrades for Rezolute and Zentalis
Leerink cut Bristol Myers and raised Zentalis. Barclays lowered uniQure. Cantor upgraded Rezolute. New Buy calls on Ovid, Maravai, and Regenxbio.
Zentalis Pharmaceuticals Gets Outperform Rating from Mizuho on Azenosertib Potential
Analyst highlights 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib.